Immunophenotyping of acute myeloid leukaemia: Relevance of analysing different lineage-associated markers

Francesco Lo Coco, Daniela Pasqualetti, Manuela Lopez, Enrico Panzini, Alfonso Gentile, Roberto Latagliata, Bruno Monarca, Giulio De Rossi

Research output: Contribution to journalArticlepeer-review


The immunophenotype of 135 previously untreated patients with FAB defined acute myeloid leukaemia (AML) was studied at diagnosis. The panel of reagents included monoclonal antibodies (MoAb) recognising myeloid-associated determinants (CD11, CD13, CD14, CD33 and others) as well as MoAb directed towards lymphoid antigens (CD7, CD10, CD19) and TdT. The results indicate that CD13 and/or CD33 are consistently expressed in AML and only rarely in ALL blasts (131/135 +ve cases, versus 4/130 in ALL). Lymphoid antigen expression was rarely detected when CD10 and CD19 were investigated in AML (0.9% and 2% +ve cases, respectively), whereas significant positivities were found for TdT and CD7 (20% and 10% respectively). Concerning FAB subtypes, two new MoAb (LAM3 and LAM7) proved very useful in the specific recognition of AML with monocytic features. The phenotype CD13+ and/or CD33+, CD9+, HLA-DR- was found to be almost exclusive for M3 AML. The response to induction chemotherapy was analysed in CD7+ and in TdT+ patients. In the latter group a statistically significant lower response rate was found with respect to TdT-ve-AML patients.

Original languageEnglish
Pages (from-to)235-240
Number of pages6
Issue number5
Publication statusPublished - May 1989


  • Acute myeloid leukaemia
  • Lymphoid-associated antigens
  • Monoclonal antibodies
  • Myeloid-associated antigens

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Immunophenotyping of acute myeloid leukaemia: Relevance of analysing different lineage-associated markers'. Together they form a unique fingerprint.

Cite this